FTO inhibitors can be effective in sensitizing melanoma tumor tissues to anti-PD-1 blockade immunotherapy and at the same time in promoting IFN-γ induced killing, which is also essential for the ICB response (110, 111). This evidence concerns the gene PDCD1 and neoplasm.